A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

ABSTRACT:

Background

The relapse after chimeric antigen receptor (CAR) T-cell therapy remains a critical challenge, and the optimal timing and treatment strategies for CAR T urgently need to be explored. Autologous hematopoietic stem cell transplantation (auto-HSCT) demonstrates comparable leukemia-free survival (LFS) and overall survival (OS) in patients who rapidly achieve MRD-negative complete remission (CR) compared with allogeneic HSCT (allo-HSCT). Thus, combining CAR T cells with auto-HSCT may represent a promising treatment strategy. The trial registration is ClinicalTrials.gov identifier NCT05470777.

Methods

This phase 2 trial evaluated the safety and efficacy of sequential CD22/CD19 CAR T cells combined with an auto-HSCT "sandwich" strategy in patients with Philadelphia chrom

SUBMITTER: Qian CS 

PROVIDER: S-EPMC12592823 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature